How are advanced dressings regulated?

Advanced dressings, depending on their composition and intended use (e.g., antimicrobial properties, absorbency), are regulated as medical devices. Their classification (e.g., FDA Class I, II, or EU MDR Class I, IIa) determines the specific pre-market requirements and conformity assessment procedures they must undergo.

What are Cellular and Tissue Products (CTPs)?

CTPs, often called skin substitutes, are biological products used to cover wounds and promote healing, particularly for severe burns or chronic ulcers. They can be derived from human, animal, or engineered sources and are subject to rigorous regulatory oversight, such as FDA 21 CFR Part 1271 for human cells, tissues, and cellular and tissue-based products (HCT/Ps).

All terms

Market SegmentsStrategic Landscape

Wound Care

Devices and biologics for managing acute and chronic wounds.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Wound care includes negative-pressure wound therapy (NPWT, e.g., 3M/KCI V.A.C.), advanced dressings, cellular and tissue products (CTPs/skin substitutes), and emerging electrical stimulation and oxygen therapies. Products include advanced dressings, negative pressure wound therapy and skin substitutes. Coverage of skin substitutes has drawn CMS attention, with local coverage policies tightening evidence requirements. Outcomes such as healing rate and time to closure drive adoption.

What the regulation says

Wound care products are subject to classification based on their risk to patients, which dictates the regulatory pathway and pre-market submission requirements, as per FDA 21 CFR Part 860 and EU MDR Article 51. Devices such as advanced dressings typically fall into lower risk classes, while implantable or biologically derived products, like cellular and tissue products, face more stringent controls and data requirements. Manufacturers must demonstrate safety and effectiveness for their intended use, aligning with principles found in ISO 13485 for quality management systems.

What this means in practice

Diabetic foot ulcers and venous leg ulcers drive demand. CMS LCDs on skin substitutes have repeatedly reshaped commercial dynamics.

Examples

A company developing an antimicrobial wound dressing must provide biocompatibility data and demonstrate the dressing's effectiveness against relevant pathogens.
A manufacturer of a new electrical stimulation device for chronic wounds needs to conduct clinical trials to prove its safety and efficacy in promoting wound closure.
A cellular therapy product for diabetic foot ulcers requires extensive pre-clinical testing and clinical data to support its claims of tissue regeneration and wound healing.

Common pitfalls

•A common pitfall is misclassifying a novel wound care product, leading to incorrect regulatory submissions and delays. Another mistake is failing to adequately validate sterilization processes for sterile wound care devices. Manufacturers often underestimate the clinical data required for advanced wound care therapies, especially those involving biological components.
•Overlooking specific labeling requirements for combination products, such as drug-device wound dressings, can lead to non-compliance.
•Ignoring post-market surveillance data for long-term wound healing outcomes can result in missed opportunities for product improvements or safety signals.

Frequently asked questions

NPWT is a therapeutic technique using a vacuum dressing to promote healing in acute or chronic wounds and enhance healing of second and third degree burns. It involves applying controlled negative pressure to the wound bed through a sealed dressing, facilitating fluid removal and promoting tissue granulation.

Grouped by theme

Latest in MedTech

Sources

4 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 3

Link health: 4 verified· last checked 2026-06-20· added official documents checked 2026-11-01

WoundSource·1MedTech Dive·1AdvaMed·1FDA·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Market Segments0 / 38

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Market Segments
Sources: 4
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Devices and biologics for managing acute and chronic wounds.

·Diabetic foot ulcers and venous leg ulcers drive demand.
·CMS LCDs on skin substitutes have repeatedly reshaped commercial dynamics.
·Products include advanced dressings, negative pressure wound therapy and skin substitutes.

Remember this

Watch out: A common pitfall is misclassifying a novel wound care product, leading to incorrect regulatory submissions and delays. Another mistake is failing to adequately validate sterilization processes for sterile wound care devices. Manufacturers often underestimate the clinical data required for advanced wound care therapies, especially those involving biological components.

You may also need

Auto-suggested from Market Segments and shared keywords.

All Market Segments terms